1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Association of race/ethnicity and insurance with survival in patients with diffuse large B‐cell lymphoma in a large real‐world cohort

      research-article

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The large real‐world EHR dataset Flatiron has shown that race was not significantly associated with poorer survival in patients with DLBCL. Medicaid insurance status was significantly associated with poorer overall survival and time to second‐line therapy or death due to any cause in patients with DLBCL aged <65 years.

          Abstract

          Objective

          Few studies have evaluated disparities in race, ethnicity, and health insurance in real‐world health outcomes for patients with diffuse large B‐cell lymphoma (DLBCL). This study aimed to evaluate association between racial disparities and health insurance with real‐world health outcomes.

          Methods

          Patients with DLBCL (January 2011–July 2021) treated with first‐line therapy were selected from a real‐world database. Variables of interest included race/ethnicity, health insurance type (Medicaid, Commercial) by patient age (<65, ≥65 years), stage at diagnosis, overall survival (OS), and time to second‐line therapy or death due to any cause (TTNTD).

          Results

          Among 5362 patients with DLBCL (82% White, 7% Black, 8% Hispanic/Latino, 3% Asian), White patients were older (mean age, 66.7 vs. 59.3–62.5 years) and less likely to have Medicaid insurance (1.7% vs. 3.4%–5.9%). Adjusted hazard ratios (aHR) for OS (Black, 0.88 [95% confidence interval, 0.72–1.07]; Hispanic/Latino, 0.84 [0.70–1.03]; Asian, 0.82 [0.59–1.16]) and TTNTD (Black, 0.89 [0.75–1.05]; Hispanic/Latino, 0.85 [0.73–1.00]; Asian, 1.11 [0.86–1.43]) were similar to those of White patients. Among patients aged <65 years, Medicaid‐insured versus Commercially insured patients had more advanced disease (stage III–IV, 66% vs. 48%), worse OS (aHR, 0.52 [0.34–0.80]; p = 0.003), and shorter TTNTD (aHR, 0.70 [0.49–0.99]; p = 0.044).

          Conclusions

          There was no statistically significant difference in these variables/outcomes between Medicaid‐insured and commercially insured patients aged ≥65 years. Medicaid‐insured status was significantly associated with poorer OS and TTNTD in patients with DLBCL aged <65 years but not in those aged ≥65 years, with or without adjusting for other baseline characteristics. Race was not significantly associated with these outcomes.

          Related collections

          Most cited references19

          • Record: found
          • Abstract: found
          • Article: not found

          Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study

          Publisher's Note: There is an [Related article:] Inside Blood Commentary on this article in this issue. SCHOLAR-1 is the first patient-level analysis of outcomes of refractory DLBCL from 2 large randomized trials and 2 academic databases. SCHOLAR-1 demonstrated poor outcomes in patients with refractory DLBCL, supporting a need for more effective therapies for these patients. Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma. Although 5-year survival rates in the first-line setting range from 60% to 70%, up to 50% of patients become refractory to or relapse after treatment. Published analyses of large-scale outcome data from patients with refractory DLBCL are limited. SCHOLAR-1, an international, multicohort retrospective non-Hodgkin lymphoma research study, retrospectively evaluated outcomes in patients with refractory DLBCL which, for this study, was defined as progressive disease or stable disease as best response at any point during chemotherapy (>4 cycles of first-line or 2 cycles of later-line therapy) or relapsed at ≤12 months from autologous stem cell transplantation. SCHOLAR-1 pooled data from 2 phase 3 clinical trials (Lymphoma Academic Research Organization-CORAL and Canadian Cancer Trials Group LY.12) and 2 observational cohorts (MD Anderson Cancer Center and University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence). Response rates and overall survival were estimated from the time of initiation of salvage therapy for refractory disease. Among 861 patients, 636 were included on the basis of refractory disease inclusion criteria. For patients with refractory DLBCL, the objective response rate was 26% (complete response rate, 7%) to the next line of therapy, and the median overall survival was 6.3 months. Twenty percent of patients were alive at 2 years. Outcomes were consistently poor across patient subgroups and study cohorts. SCHOLAR-1 is the largest patient-level pooled retrospective analysis to characterize response rates and survival for a population of patients with refractory DLBCL.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.

            We report the outcome of patients included in the LNH-98.5 study, which compared cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) to rituximab plus CHOP (R-CHOP) therapy in 399 patients with diffuse large B-cell lymphoma (DLBCL) aged 60 to 80 years, with a median follow-up time of 10 years. Clinical event information was updated in all living patients (with the exception of 3 patients) in 2009. Survival end points were improved in patients treated with R-CHOP: the 10-year progression-free survival was 36.5%, compared with 20% with CHOP alone, and the 10-year overall survival was 43.5% compared with 27.6%. The same risk of death due to other diseases, secondary cancers, and late relapses was observed in both study arms. Relapses occurring after 5 years represented 7% of all disease progressions. The results from the 10-year analysis confirm the benefits and tolerability of the addition of rituximab to CHOP. Our findings underscore the need to treat elderly patients as young patients, with the use of curative chemotherapy.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.

              The standard treatment for patients with diffuse large-B-cell lymphoma is cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Rituximab, a chimeric monoclonal antibody against the CD20 B-cell antigen, has therapeutic activity in diffuse large-B-cell lymphoma. We conducted a randomized trial to compare CHOP chemotherapy plus rituximab with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. Previously untreated patients with diffuse large-B-cell lymphoma, 60 to 80 years old, were randomly assigned to receive either eight cycles of CHOP every three weeks (197 patients) or eight cycles of CHOP plus rituximab given on day 1 of each cycle (202 patients). The rate of complete response was significantly higher in the group that received CHOP plus rituximab than in the group that received CHOP alone (76 percent vs. 63 percent, P=0.005). With a median follow-up of two years, event-free and overall survival times were significantly higher in the CHOP-plus-rituximab group (P<0.001 and P=0.007, respectively). The addition of rituximab to standard CHOP chemotherapy significantly reduced the risk of treatment failure and death (risk ratios, 0.58 [95 percent confidence interval, 0.44 to 0.77] and 0.64 [0.45 to 0.89], respectively). Clinically relevant toxicity was not significantly greater with CHOP plus rituximab. The addition of rituximab to the CHOP regimen increases the complete-response rate and prolongs event-free and overall survival in elderly patients with diffuse large-B-cell lymphoma, without a clinically significant increase in toxicity.
                Bookmark

                Author and article information

                Contributors
                yanling.jin@roche.com
                Journal
                Cancer Med
                Cancer Med
                10.1002/(ISSN)2045-7634
                CAM4
                Cancer Medicine
                John Wiley and Sons Inc. (Hoboken )
                2045-7634
                23 August 2024
                August 2024
                : 13
                : 16 ( doiID: 10.1002/cam4.v13.16 )
                : e70032
                Affiliations
                [ 1 ] F. Hoffmann‐La Roche Ltd Mississauga Ontario Canada
                [ 2 ] Genentech, Inc. South San Francisco California USA
                [ 3 ]Present address: Data Solutions LLC Bronx New York USA
                Author notes
                [*] [* ] Correspondence

                Yanling Jin, F. Hoffmann‐La Roche Ltd, 7070 Mississauga Road, Mississauga, ON L5N 5M8, Canada.

                Email: yanling.jin@ 123456roche.com

                Article
                CAM470032 CAM4-2022-07-2807.R2
                10.1002/cam4.70032
                11342043
                39177019
                b678320b-10b5-4dc9-b423-703a9ecce9c3
                © 2024 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                : 19 January 2024
                : 07 September 2022
                : 08 July 2024
                Page count
                Figures: 4, Tables: 4, Pages: 16, Words: 6700
                Categories
                Research Article
                Research Article
                Custom metadata
                2.0
                August 2024
                Converter:WILEY_ML3GV2_TO_JATSPMC version:6.4.7 mode:remove_FC converted:23.08.2024

                Oncology & Radiotherapy
                diffuse large b‐cell lymphoma,medicaid insurance status,overall survival,time to second‐line therapy or death

                Comments

                Comment on this article